Prevalence of SARS-CoV-2 Antibody in 2,935 Healthcare Workers at 6 Major Hospitals, Daegu, Korea

J Korean Med Sci. 2021 Nov 8;36(43):e294. doi: 10.3346/jkms.2021.36.e294.

Abstract

Background: In Korea, the first community outbreak of coronavirus disease 2019 (COVID-19) occurred in Daegu on February 18, 2020. This study was performed to investigate the prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies in healthcare workers (HCWs) at 6 major hospitals in Daegu.

Methods: Blood specimens of 2,935 HCWs at 6 major hospitals in Daegu from January 2021 to February 2021 were collected. Every specimen was tested for antibody against SARS-CoV-2 using both Elecsys Anti-SARS-CoV-2 electrochemiluminescence immunoassay (Roche Diagnostics, Rotkreuz, Switzerland) and R-FIND COVID-19 IgG/M/A enzyme-linked immunosorbent assay kit (SG medical Inc., Seoul, Korea) as screening tests. If 1 or more of these screening test results was positive, 2 additional antibody tests were performed using Abbott Anti-SARS-CoV-2 IgG assay (Abbott, Abbott Park, IL, USA) and cPass SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript USA Inc., Piscataway, NJ, USA). If 2 or more of the total 4 test results were positive, it was determined as positive for the antibody against SARS-CoV-2.

Results: According to the criteria of SARS-CoV-2 antibody positivity determination, 12 subjects were determined as positive. The overall positive rate of the SARS-CoV-2 antibody was 0.41% (12/2,935). Of the 12 subjects determined as positive, 7 were diagnosed with COVID-19, and the remaining 5 were nondiagnosed cases of COVID-19.

Conclusion: In early 2021, the overall seroprevalence of SARS-CoV-2 antibody among HCW located in Daegu was 0.41%, and 0.17% excluding COVID-19 confirmed subjects. These results were not particularly high compared with the general public and were much lower than HCWs in other countries.

Keywords: COVID-19; Healthcare Worker; Neutralizing Antibody; SARS-CoV-2 Antibody.

MeSH terms

  • Adult
  • Aged
  • Antibodies, Neutralizing
  • Antibodies, Viral / blood*
  • Antibody Specificity
  • COVID-19 / diagnosis*
  • COVID-19 / epidemiology
  • COVID-19 / immunology*
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Health Personnel / statistics & numerical data*
  • Hospitals
  • Humans
  • Immunoglobulin A / blood
  • Immunoglobulin G / blood*
  • Immunoglobulin M / blood
  • Male
  • Middle Aged
  • Prevalence
  • Republic of Korea / epidemiology
  • SARS-CoV-2

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin A
  • Immunoglobulin G
  • Immunoglobulin M